Yuksel B, Greenough A
Department of Child Health, King's College Hospital, London, United Kingdom.
Eur J Pediatr. 1991 Oct;150(12):854-7. doi: 10.1007/BF01955008.
Twelve preterm infants, median gestational age 31.5 weeks, were entered into a randomised, placebo-controlled trial of bronchodilator therapy. Their postnatal age was a median of 17.5 months and all suffered from recurrent respiratory symptoms. The infants received either inhaled placebo or 40 micrograms of ipratropium bromide (active therapy) three times a day utilising a coffee cup as a spacer device. Each therapy was administered for 2 weeks. The symptom score during the active period was reduced by 59% compared to the placebo period (P less than 0.01) and this was associated with 38% improvement in lung function in the active period compared to a 20% change in functional residual capacity over the placebo period (P less than 0.01). We conclude inhaled ipratropium bromide appears to be an effective treatment for symptomatic infants at follow up.
12名胎龄中位数为31.5周的早产婴儿被纳入一项支气管扩张剂治疗的随机、安慰剂对照试验。他们的出生后年龄中位数为17.5个月，均患有反复呼吸道症状。婴儿们使用咖啡杯作为储雾罐，每天吸入三次安慰剂或40微克异丙托溴铵（活性治疗）。每种治疗持续2周。与安慰剂期相比，活性期的症状评分降低了59%（P<0.01），且活性期肺功能改善了38%，而安慰剂期功能残气量变化为20%（P<0.01）。我们得出结论，吸入异丙托溴铵似乎是对有症状婴儿随访时的一种有效治疗方法。
